FDA Setback Clouds Timeline For Bright Minds Biosciences' Pediatric Epilepsy Trials
The FDA places a partial clinical hold on Bright Minds Biosciences' Phase 2 epilepsy study after mouse toxicity and pediatric data concerns.
Share
Why It Matters
The FDA hit the brakes on Bright Minds' epilepsy medicine study. They want more safety proof before kids can test it.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.